The University of Colorado recently received a payment of $30M following the monetization of its royalty streams to several urological uses of botulinum toxin (Botox®) developed at the University’s Anschutz Medical Campus in the late 1990’s. CU researcher Richard Schmidt developed Botox-based treatments for overactive bladder (OAB) and benign prostatic hyperplasia (BPH).
Botox is marketed by Irvine, CA-based Allergan, Inc., who licensed these new uses of Botox from CU. The U.S. Food and Drug Administration (FDA) approved Botox to treat overactive bladder associated with neurological conditions in August 2011; clinical trials are also underway for treatment of BPH and idiopathic OAB.
16 hours ago